Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Atherosclerosis

Retrieve available abstracts of 112 articles:
HTML format

Single Articles

    June 2024
  1. TADA H, Takamura M
    Toward personalized medicine in patients with familial hypercholesterolemia.
    Atherosclerosis. 2024 Jun 18:118522. doi: 10.1016/j.atherosclerosis.2024.118522.

    May 2024
  2. BERBERICH AJ, Hegele RA
    Pancreatitis risk in genetic subtypes of multifactorial chylomicronemia syndrome.
    Atherosclerosis. 2024;392:117528.

    April 2024
    How can we improve the prognosis of patients with homozygous familial hypercholesterolemia?
    Atherosclerosis. 2024 Apr 16:117551. doi: 10.1016/j.atherosclerosis.2024.117551.

  4. HENDY LE, Spees LP, Tak C, Carpenter DM, et al
    An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients.
    Atherosclerosis. 2024;393:117541.
    PubMed     Abstract available

  5. IBRAHIM S, Nurmohamed NS, Nierman MC, de Goeij JN, et al
    Enhanced identification of familial hypercholesterolemia using central laboratory algorithms.
    Atherosclerosis. 2024;393:117548.
    PubMed     Abstract available

  6. BASHIR B, Kwok S, Wierzbicki AS, Jones A, et al
    Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: Implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS).
    Atherosclerosis. 2024;391:117476.
    PubMed     Abstract available

    March 2024
  7. REIJMAN MD, Kusters DM, Groothoff JW, Arbeiter K, et al
    Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN.
    Atherosclerosis. 2024;392:117525.
    PubMed     Abstract available

  8. ALONSO R, Arroyo-Olivares R, Diaz-Diaz JL, Fuentes-Jimenez F, et al
    Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.
    Atherosclerosis. 2024 Mar 16:117516. doi: 10.1016/j.atherosclerosis.2024.117516.
    PubMed     Abstract available

  9. MELNES T, Bogsrud MP, Christensen JJ, Rundblad A, et al
    Gene expression profiling in elderly patients with familial hypercholesterolemia with and without coronary heart disease.
    Atherosclerosis. 2024;392:117507.
    PubMed     Abstract available

  10. ESCATE R, Padro T, Perez de Isla L, Fuentes F, et al
    Circulating miR-6821-5p levels and coronary calcification in asymptomatic familial hypercholesterolemia patients.
    Atherosclerosis. 2024;392:117502.
    PubMed     Abstract available

    Diagnostic challenge of an APOB variant of uncertain significance resolved by transheterozygosity with a pathological LDLR variant and clinical response to therapy.
    Atherosclerosis. 2024;390:117460.

    February 2024
  12. GUAY SP, Paquette M, Taschereau A, Girard L, et al
    Acute pancreatitis risk in multifactorial chylomicronemia syndrome depends on the molecular cause of severe hypertriglyceridemia.
    Atherosclerosis. 2024 Feb 27:117489. doi: 10.1016/j.atherosclerosis.2024.117489.
    PubMed     Abstract available

    January 2024
  13. RAGGI P, Takyar FM, Gadiyaram V, Zhang C, et al
    Differential effect of atorvastatin and pravastatin on thoracic spine attenuation: A sub-analysis of a randomized clinical trial.
    Atherosclerosis. 2024;388:117425.
    PubMed     Abstract available

    December 2023
  14. WODAJE T, Mahdi A, Venkateshvaran A, Habel H, et al
    Higher prevalence of coronary microvascular dysfunction in asymptomatic individuals with high levels of lipoprotein(a) with and without heterozygous familial hypercholesterolaemia.
    Atherosclerosis. 2023;389:117439.
    PubMed     Abstract available

  15. ANDRADE MM, Neto Goncalves T, Cruz D
    Familial hypercholesterolemia diagnostic challenge: Is Artificial Intelligence the key?
    Atherosclerosis. 2023 Dec 27:117435. doi: 10.1016/j.atherosclerosis.2023.117435.

  16. FISHBEIN I, Inamdar VV, Alferiev IS, Bratinov G, et al
    Hypercholesterolemia exacerbates in-stent restenosis in rabbits: Studies of the mitigating effect of stent surface modification with a CD47-derived peptide.
    Atherosclerosis. 2023;390:117432.
    PubMed     Abstract available

    November 2023
  17. MOLOKHIA M, Wierzbicki AS, Williams H, Kirubakaran A, et al
    Assessment of ethnic inequalities in diagnostic coding of familial hypercholesterolaemia (FH): A cross-sectional database study in Lambeth, South London.
    Atherosclerosis. 2023;388:117353.
    PubMed     Abstract available

  18. ZUBIRAN R, Vargas-Vazquez A, Olvera FDR, Cruz-Bautista I, et al
    Performance of the enhanced Sampson-NIH equation for VLDL-C and LDL-C in a population with familial combined hyperlipidemia.
    Atherosclerosis. 2023;386:117364.
    PubMed     Abstract available

  19. HOLVEN KB, Roeters van Lennep J
    Sex differences in lipids: A life course approach.
    Atherosclerosis. 2023;384:117270.
    PubMed     Abstract available

  20. GOLDBERG AC, Banach M, Catapano AL, Duell PB, et al
    Evaluation of the efficacy and safety of bempedoic acid in women and men: Pooled analyses from phase 3 trials.
    Atherosclerosis. 2023;384:117192.
    PubMed     Abstract available

    October 2023
  21. KATZMANN JL, Laufs U
    Liver transplantation for homozygous familial hypercholesterolemia: Cure for a genetic disease?
    Atherosclerosis. 2023 Oct 16:117337. doi: 10.1016/j.atherosclerosis.2023.117337.

  22. JUNNA N, Ruotsalainen S, Ripatti P, FinnGen, et al
    Novel Finnish-enriched variants causing severe hypercholesterolemia and their clinical impact on coronary artery disease.
    Atherosclerosis. 2023 Oct 12:117327. doi: 10.1016/j.atherosclerosis.2023.117327.
    PubMed     Abstract available

  23. PAGE MM, Hardikar W, Alex G, Bates S, et al
    Long-term outcomes of liver transplantation for homozygous familial hypercholesterolaemia in Australia and New Zealand.
    Atherosclerosis. 2023 Oct 10:117305. doi: 10.1016/j.atherosclerosis.2023.117305.
    PubMed     Abstract available

    Improving pediatric familial hypercholesterolemia diagnosis by looking deeper into families.
    Atherosclerosis. 2023 Oct 1:117317. doi: 10.1016/j.atherosclerosis.2023.117317.

    September 2023
  25. ALBUQUERQUE J, Medeiros AM, Alves AC, Jannes CE, et al
    Generation and validation of a classification model to diagnose familial hypercholesterolaemia in adults.
    Atherosclerosis. 2023;383:117314.
    PubMed     Abstract available

    August 2023
  26. CASULA M, Gazzotti M, Capra ME, Olmastroni E, et al
    Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study.
    Atherosclerosis. 2023 Aug 12:117231. doi: 10.1016/j.atherosclerosis.2023.117231.
    PubMed     Abstract available

  27. HON A, Hsu JJ, Zambrano A, Xia Y, et al
    Effects of activity levels on aortic calcification in hyperlipidemic mice as measured by microPETmicroCT.
    Atherosclerosis. 2023;380:117198.
    PubMed     Abstract available

  28. SHAPIRO MD, Taub PR, Louie MJ, Lei L, et al
    Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials.
    Atherosclerosis. 2023;378:117182.
    PubMed     Abstract available

  29. MURPHY JM, Jeong K, Tran DTK, Cioffi DL, et al
    Nuclear FAK in endothelium: An intrinsic inhibitor of NF-kappaB activation in atherosclerosis.
    Atherosclerosis. 2023;379:117189.
    PubMed     Abstract available

    July 2023
  30. SIMONEN P, Oorni K, Sinisalo J, Strandberg TE, et al
    High cholesterol absorption: A risk factor of atherosclerotic cardiovascular diseases?
    Atherosclerosis. 2023;376:53-62.
    PubMed     Abstract available

    June 2023
  31. JONES A, Peers K, Wierzbicki AS, Ramachandran R, et al
    Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS).
    Atherosclerosis. 2023;375:67-74.
    PubMed     Abstract available

  32. COSIN-SALES J, Campuzano Ruiz R, Diaz Diaz JL, Escobar Cervantes C, et al
    Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain.
    Atherosclerosis. 2023;375:38-44.
    PubMed     Abstract available

    May 2023
  33. DOI T, Langsted A, Nordestgaard BG
    Dual elevated remnant cholesterol and C-reactive protein in myocardial infarction, atherosclerotic cardiovascular disease, and mortality.
    Atherosclerosis. 2023 May 13:S0021-9150(23)00204.
    PubMed     Abstract available

  34. SONMEZ A, Demirci I, Haymana C, Tasci I, et al
    Clinical characteristics of adult and paediatric patients with familial hypercholesterolemia: A real-life cross-sectional study from the Turkish National Database.
    Atherosclerosis. 2023;375:9-20.
    PubMed     Abstract available

    April 2023
  35. RODRIGUEZ-BORJABAD C, Narveud I, Christensen JJ, Ibarretxe D, et al
    Association between Nordic and Mediterranean diets with lipoprotein phenotype assessed by (1)HNMR in children with familial hypercholesterolemia.
    Atherosclerosis. 2023;373:38-45.
    PubMed     Abstract available

  36. SCHREUDER MM, Hamkour S, Siegers KE, Holven KB, et al
    LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis.
    Atherosclerosis. 2023 Apr 13:S0021-9150(23)00139.
    PubMed     Abstract available

  37. HEDEGAARD BS, Bork CS, Kanstrup HL, Thomsen KK, et al
    Genetic testing increases the likelihood of a diagnosis of familial hypercholesterolaemia among people referred to lipid clinics: Danish national study.
    Atherosclerosis. 2023;373:10-16.
    PubMed     Abstract available

    March 2023
  38. TADA H, Nomura A, Nohara A, Usui S, et al
    Attainment of the low-density lipoprotein cholesterol treatment target and prognosis of heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2023 Mar 17:S0021-9150(23)00103.
    PubMed     Abstract available

    December 2022
  39. FARIA R, Saramago P, Cox E, Weng S, et al
    How does cholesterol burden change the case for investing in familial hypercholesterolaemia? A cost-effectiveness analysis.
    Atherosclerosis. 2022 Dec 29:S0021-9150(22)01557.
    PubMed     Abstract available

    Lipoprotein(a) and familial hypercholesterolemia: Partners in crime in heritable hyperlipidemia.
    Atherosclerosis. 2022 Dec 24:S0021-9150(22)01570.

  41. COUTINHO ER, Miname MH, Rocha VZ, Bittencourt MS, et al
    Cardiovascular disease onset in old people with severe hypercholesterolemia.
    Atherosclerosis. 2022;365:9-14.
    PubMed     Abstract available

    November 2022
  42. TROMP TR, Ibrahim S, Nurmohamed NS, Peter J, et al
    Use of Lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemia.
    Atherosclerosis. 2022 Nov 29:S0021-9150(22)01530.
    PubMed     Abstract available

  43. HU YX, You HM, Zhu RF, Liang YL, et al
    Establishment of a lipid metabolism disorder model in ApoEb mutant zebrafish.
    Atherosclerosis. 2022;361:18-29.
    PubMed     Abstract available

    October 2022
  44. CEFALU AB, D'Erasmo L, Iannuzzo G, Noto D, et al
    Efficacy and safety of lomitapide in familial chylomicronaemia syndrome.
    Atherosclerosis. 2022;359:13-19.
    PubMed     Abstract available

    September 2022
  45. ZHU Q, Xiao Y, Jiang M, Liu X, et al
    N-acetylcysteine attenuates atherosclerosis progression in aging LDL receptor deficient mice with preserved M2 macrophages and increased CD146.
    Atherosclerosis. 2022;357:41-50.
    PubMed     Abstract available

    August 2022
  46. MICHIKURA M, Hori M, Ogura M, Hosoda K, et al
    The impact of gene variants on the thickness and softness of the Achilles tendon in familial hypercholesterolemia.
    Atherosclerosis. 2022;358:41-46.
    PubMed     Abstract available

  47. SVENDSEN K, Olsen T, Vinknes KJ, Mundal LJ, et al
    Risk of stroke in genetically verified familial hypercholesterolemia: A prospective matched cohort study.
    Atherosclerosis. 2022;358:34-40.
    PubMed     Abstract available

  48. MIZUTA MH, Santos RD
    Difficulties in gauging atherosclerotic cardiovascular disease risk heterogeneity in familial hypercholesterolemia.
    Atherosclerosis. 2022 Aug 22. pii: S0021-9150(22)01389.

    July 2022
  49. MCKAY AJ, Gunn LH, Ray KK
    Assessing the external validity of the SAFEHEART risk prediction model in patients with familial hypercholesterolaemia in an English routine care cohort.
    Atherosclerosis. 2022 Jul 21. pii: S0021-9150(22)01352.
    PubMed     Abstract available

    June 2022
  50. JAHN B, Santamaria J, Dieplinger H, Binder CJ, et al
    Familial hypercholesterolemia: A systematic review of modeling studies on screening interventions.
    Atherosclerosis. 2022;355:15-29.
    PubMed     Abstract available

  51. TAMURA K, Kumagai T, Kobayashi K
    Possible clinical usefulness of polygenic risk scores among patients with established atherosclerotic cardiovascular disease.
    Atherosclerosis. 2022;350:100-101.

    May 2022
  52. CHEMELLO K, Chan DC, Lambert G, Watts GF, et al
    Recent advances in demystifying the metabolism of lipoprotein(a).
    Atherosclerosis. 2022;349:82-91.
    PubMed     Abstract available

  53. PEDERIVA C, Capra ME, Biasucci G, Banderali G, et al
    Lipoprotein(a) and family history for cardiovascular disease in paediatric patients: A new frontier in cardiovascular risk stratification. Data from the LIPIGEN paediatric group.
    Atherosclerosis. 2022;349:233-239.
    PubMed     Abstract available

  54. RIDER DA, Eisermann M, Loffler K, Aleku M, et al
    Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease.
    Atherosclerosis. 2022;349:240-247.
    PubMed     Abstract available

    April 2022
  55. TENG H, Gao Y, Wu C, Zhang H, et al
    Prevalence and patient characteristics of familial hypercholesterolemia in a Chinese population aged 35-75 years: Results from China PEACE Million Persons Project.
    Atherosclerosis. 2022;350:58-64.
    PubMed     Abstract available

    March 2022
  56. NOTO D, Spina R, Giammanco A, Barbagallo CM, et al
    Diagnosis of familial hypercholesterolemia in a large cohort of Italian genotyped hypercholesterolemic patients.
    Atherosclerosis. 2022;347:63-67.
    PubMed     Abstract available

  57. MULDER JWCM, Kranenburg LW, Treling WJ, Hovingh GK, et al
    Quality of life and coping in Dutch homozygous familial hypercholesterolemia patients: A qualitative study.
    Atherosclerosis. 2022 Mar 12. pii: S0021-9150(22)00136.
    PubMed     Abstract available

    February 2022
  58. STOCK JK
    Homozygous Familial Hypercholesterolaemia International Clinical Collaboration (HICC) registry: Levelling up access to treatment urgently needed.
    Atherosclerosis. 2022 Feb 20. pii: S0021-9150(22)00077.

    January 2022
  59. PAQUETTE M, Baass A
    Polygenic risk scores for cardiovascular disease prediction in the clinical practice: Are we there?
    Atherosclerosis. 2022;340:46-47.

    December 2021
  60. TRINDER M, Vikulova D, Pimstone S, Mancini GBJ, et al
    Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia.
    Atherosclerosis. 2021;340:35-43.
    PubMed     Abstract available

  61. TADA H, Okada H, Nohara A, Takamura M, et al
    Genetic mutations, regression of Achilles tendon thickness, and cardiovascular events among patients with familial hypercholesterolemia.
    Atherosclerosis. 2021;340:28-34.
    PubMed     Abstract available

    November 2021
  62. CHAKRABORTY A, Pang J, Chan DC, Ellis KL, et al
    Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a).
    Atherosclerosis. 2021 Nov 12. pii: S0021-9150(21)01417.
    PubMed     Abstract available

  63. SANCHEZ-RAMOS A, Fernandez-Labandera C, Vallejo-Vaz A, Bonacho EC, et al
    Prevalence of familial hypercholesterolemia phenotype and ten-year risk of cardiovascular events in a working population in primary prevention: The ICARIA study.
    Atherosclerosis. 2021;338:39-45.
    PubMed     Abstract available

  64. TROMP TR, Cupido AJ, Reeskamp LF, Stroes ESG, et al
    Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia.
    Atherosclerosis. 2021 Nov 2. pii: S0021-9150(21)01413.
    PubMed     Abstract available

    October 2021
  65. LEONARDI-BEE J, Boateng C, Faria R, Eliman K, et al
    Effectiveness of cascade testing strategies in relatives for familial hypercholesterolemia: A systematic review and meta-analysis.
    Atherosclerosis. 2021;338:7-14.
    PubMed     Abstract available

    September 2021
  66. STOCK JK
    Global Familial Hypercholesterolaemia Studies Collaboration (FHSC).
    Atherosclerosis. 2021 Sep 23. pii: S0021-9150(21)01361.

  67. PAQUETTE M, Bernard S, Baass A
    Hemoglobin concentration, hematocrit and red blood cell count predict major adverse cardiovascular events in patients with familial hypercholesterolemia.
    Atherosclerosis. 2021;335:41-46.
    PubMed     Abstract available

  68. KLEVMOEN M, Bogsrud MP, Retterstol K, Svilaas T, et al
    Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia.
    Atherosclerosis. 2021;335:8-15.
    PubMed     Abstract available

    August 2021
  69. MARCO-BENEDI V, Cenarro A, Laclaustra M, Larrea-Sebal A, et al
    Lipoprotein(a) in hereditary hypercholesterolemia: Influence of the genetic cause, defective gene and type of mutation.
    Atherosclerosis. 2021 Aug 23. pii: S0021-9150(21)01270.
    PubMed     Abstract available

  70. DYRBUS K, Gasior M, Desperak P, Trzeciak P, et al
    Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry.
    Atherosclerosis. 2021;333:16-23.
    PubMed     Abstract available

  71. TOMBLING BJ, Zhang Y, Huang YH, Craik DJ, et al
    The emerging landscape of peptide-based inhibitors of PCSK9.
    Atherosclerosis. 2021;330:52-60.
    PubMed     Abstract available

    July 2021
  72. KATZMANN JL, Lehmann M, Tunnemann-Tarr A, An Haack I, et al
    Cutaneous manifestations in familial hypercholesterolaemia.
    Atherosclerosis. 2021 Jul 11. pii: S0021-9150(21)01236.
    PubMed     Abstract available

  73. KHALIL YA, Rabes JP, Boileau C, Varret M, et al
    APOE gene variants in primary dyslipidemia.
    Atherosclerosis. 2021;328:11-22.
    PubMed     Abstract available

  74. ALVES AC, Azevedo S, Benito-Vicente A, Graca R, et al
    LDLR variants functional characterization: Contribution to variant classification.
    Atherosclerosis. 2021;329:14-21.
    PubMed     Abstract available

    June 2021
  75. MALO AI, Girona J, Ibarretxe D, Rodriguez-Borjabad C, et al
    Serum glycoproteins A and B assessed by (1)H-NMR in familial hypercholesterolemia.
    Atherosclerosis. 2021;330:1-7.
    PubMed     Abstract available

  76. PAQUETTE M, Fantino M, Bernard S, Baass A, et al
    Paternal inheritance predicts earlier cardiovascular event onset in patients with familial hypercholesterolemia.
    Atherosclerosis. 2021;329:9-13.
    PubMed     Abstract available

  77. ROOS CM, Zhang B, Hagler MA, Arghami A, et al
    MnSOD protects against vascular calcification independent of changes in vascular function in hypercholesterolemic mice.
    Atherosclerosis. 2021 Jun 8. pii: S0021-9150(21)00276.
    PubMed     Abstract available

    May 2021
  78. REESKAMP LF, Nurmohamed NS, Bom MJ, Planken RN, et al
    Marked plaque regression in homozygous familial hypercholesterolemia.
    Atherosclerosis. 2021;327:13-17.
    PubMed     Abstract available

    April 2021
  79. BRANDTS J, Dharmayat KI, Vallejo-Vaz AJ, Azar Sharabiani MT, et al
    A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia.
    Atherosclerosis. 2021;325:46-56.
    PubMed     Abstract available

  80. INGOE L, Potter A, Musson S, Neely D, et al
    Improving the identification of patients with a genetic diagnosis of familial hypercholesterolaemia in primary care: A strategy to achieve the NHS long term plan.
    Atherosclerosis. 2021;325:38-45.
    PubMed     Abstract available

    Benefits and harms of LDL-cholesterol-lowering therapy in older people must be established through valid and clinically relevant evidence.
    Atherosclerosis. 2021;323:57-58.

  82. LIMA JG, Helena C Nobrega L, Moura Bandeira FT, Pires Sousa AG, et al
    A novel GPIHBP1 mutation related to familial chylomicronemia syndrome: A series of cases.
    Atherosclerosis. 2021;322:31-38.
    PubMed     Abstract available

  83. JO SH, Han SH, Kim SH, Eckel RH, et al
    Cardiovascular effects of omega-3 fatty acids: Hope or hype?
    Atherosclerosis. 2021;322:15-23.
    PubMed     Abstract available

    March 2021
  84. BUONUOMO PS, Mastrogiorgio G, Leone G, Rana I, et al
    Evolocumab in the management of children <10 years of age affected by homozygous familial hypercholesterolemia.
    Atherosclerosis. 2021 Mar 28. pii: S0021-9150(21)00147.

  85. ELLINS EA, Watkins S, Rees DA, Datta DBN, et al
    Acute effect of a single session of lipoprotein apheresis on central haemodynamics in patients with familial hypercholesterolaemia.
    Atherosclerosis. 2021 Mar 27. pii: S0021-9150(21)00144.

    Correspondence on: "Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features".
    Atherosclerosis. 2021 Mar 20. pii: S0021-9150(21)00125.

  87. ZIGMOND ZM, Song L, Martinez L, Lassance-Soares RM, et al
    c-Kit expression in smooth muscle cells reduces atherosclerosis burden in hyperlipidemic mice.
    Atherosclerosis. 2021 Mar 9. pii: S0021-9150(21)00112.
    PubMed     Abstract available

  88. BANACH M, Penson PE
    Lipid-lowering therapies: Better together.
    Atherosclerosis. 2021;320:86-88.

    February 2021
  89. LEREN TP, Bogsrud MP
    Molecular genetic testing for autosomal dominant hypercholesterolemia in 29,449 Norwegian index patients and 14,230 relatives during the years 1993-2020.
    Atherosclerosis. 2021;322:61-66.
    PubMed     Abstract available

  90. REESKAMP LF, Balvers M, Peter J, van de Kerkhof L, et al
    Intronic variant screening with targeted next-generation sequencing reveals first pseudoexon in LDLR in familial hypercholesterolemia.
    Atherosclerosis. 2021;321:14-20.
    PubMed     Abstract available

    January 2021
  91. VUORIO A, Raal F, Kaste M, Kovanen PT, et al
    Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment.
    Atherosclerosis. 2021;320:53-60.
    PubMed     Abstract available

  92. MARCO-BENEDI V, Laclaustra M, Bea AM, Suarez-Tembra M, et al
    Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia.
    Atherosclerosis. 2021;320:47-52.
    PubMed     Abstract available

  93. FUTEMA M, Ramaswami U, Tichy L, Bogsrud MP, et al
    Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
    Atherosclerosis. 2021;319:108-117.
    PubMed     Abstract available

  94. GAUTIER T, Deckert V, Aires V, Le Guern N, et al
    Human apolipoprotein C1 transgenesis reduces atherogenesis in hypercholesterolemic rabbits.
    Atherosclerosis. 2021;320:10-18.
    PubMed     Abstract available

  95. VALLEJO-VAZ AJ, Packard CJ, Ference BA, Santos RD, et al
    LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial.
    Atherosclerosis. 2021;320:1-9.
    PubMed     Abstract available

  96. KOROSOGLOU G, Chatzizisis YS, Raggi P
    Coronary computed tomography angiography in asymptomatic patients: Still a taboo or precision medicine?
    Atherosclerosis. 2021;317:47-49.

  97. STOCK JK
    Should we treat high LDL cholesterol in 'healthy' elderly individuals?
    Atherosclerosis. 2021;317:50-51.

    December 2020
  98. RUBINO J, MacDougall DE, Sterling LR, Hanselman JC, et al
    Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
    Atherosclerosis. 2020 Dec 31. pii: S0021-9150(20)31597.
    PubMed     Abstract available

  99. SVENDSEN K, Krogh HW, Igland J, Tell GS, et al
    2.5-fold increased risk of recurrent acute myocardial infarction with familial hypercholesterolemia.
    Atherosclerosis. 2020;319:28-34.
    PubMed     Abstract available

  100. COUTINHO ER, Miname MH, Rocha VZ, Bittencourt MS, et al
    Familial hypercholesterolemia and cardiovascular disease in older individuals.
    Atherosclerosis. 2020;318:32-37.
    PubMed     Abstract available

  101. SVENDSEN K, Langslet G, Krogh HW, Brinck J, et al
    Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia.
    Atherosclerosis. 2020;316:48-52.
    PubMed     Abstract available

    November 2020
  102. REESKAMP LF, Tromp TR, Huijgen R, Stroes ESG, et al
    Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation.
    Atherosclerosis. 2020;315:68-75.
    PubMed     Abstract available

  103. PEREZ DE ISLA L, Alonso R, Gomez de Diego JJ, Muniz-Grijalvo O, et al
    Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study.
    Atherosclerosis. 2020 Nov 18. pii: S0021-9150(20)31521.
    PubMed     Abstract available

    October 2020
  104. IYEN B, Qureshi N, Weng S, Roderick P, et al
    Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: A retrospective cohort study of the UK Simon Broome register linked to national hospital records.
    Atherosclerosis. 2020 Oct 31. pii: S0021-9150(20)31491.
    PubMed     Abstract available

    September 2020
  105. BURRIS RL, Vick SC, Popovic B, Fraungruber PE, et al
    Maternal exposure to soy diet reduces atheroma in hyperlipidemic F1 offspring mice by promoting macrophage and T cell anti-inflammatory responses.
    Atherosclerosis. 2020;313:26-34.
    PubMed     Abstract available

  106. IQBAL Z, Ho JH, Adam S, France M, et al
    Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK.
    Atherosclerosis. 2020;313:126-136.
    PubMed     Abstract available

  107. BERTOLINI S, Calandra S, Arca M, Averna M, et al
    Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features.
    Atherosclerosis. 2020;312:72-78.
    PubMed     Abstract available

    May 2020
  108. TSIMIKAS S, Stroes ESG
    The dedicated "Lp(a) clinic": A concept whose time has arrived?
    Atherosclerosis. 2020;300:1-9.
    PubMed     Abstract available

  109. DE NISCO G, Hoogendoorn A, Chiastra C, Gallo D, et al
    The impact of helical flow on coronary atherosclerotic plaque development.
    Atherosclerosis. 2020;300:39-46.
    PubMed     Abstract available

    March 2020
  110. ADINOLFI LE, Petta S, Fracanzani AL, Coppola C, et al
    Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study.
    Atherosclerosis. 2020;296:40-47.
    PubMed     Abstract available

    February 2020
  111. NORDESTGAARD BG, Langlois MR, Langsted A, Chapman MJ, et al
    Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM.
    Atherosclerosis. 2020;294:46-61.
    PubMed     Abstract available

    January 2020
  112. CHIU YW, Wu CS, Chen PC, Wei YC, et al
    Risk of acute mesenteric ischemia in patients with diabetes: A population-based cohort study in Taiwan.
    Atherosclerosis. 2020;296:18-24.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hyperlipoproteinemias is free of charge.